Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1987 Nov;25(3):257–265. doi: 10.1007/BF00199156

Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma

Treatment of stage II melanoma with viral lysates

Peter Hersey 1,✉, Anne Edwards 1, Alan Coates 2, Helen Shaw 1, William McCarthy 1, Gerald Milton 1
PMCID: PMC11038013  PMID: 3677126

Abstract

A total of 80 patients with melanoma metastases in regional lymph nodes were treated by i.d. injections with a vaccine prepared from a vaccinia virus-infected allogeneic melanoma cell line; 39 patients have been followed for a 2-year period. Interim results from comparison of the treated group with 151 historical controls treated without the vaccine from September 1978 to December 1981 at the same institution and 56 non-randomized concurrent controls suggest that survival was significantly prolonged in the vaccinated group. At the 2-year period overall survival was 75% in the treated compared to 57% in the historical control group. Subset analysis showed a greater apparent benefit of vaccine therapy among patients who had metastases detected at the time of treatment of the primary melanoma (synchronous metastases), while therapy appeared less effective in patients with metastases detected at some time after treatment of the primary (delayed metastases). In the latter only those with one lymph node appeared to benefit from the treatment whereas in patients with synchronous metastases patients with three or more nodes as well as one node appeared to have improved survival. The survival rates at 2 years for treated patients with synchronous metastases in one, two, three or more lymph nodes was 100%, 83% and 79% respectively compared with that of 82%, 86% and 47% respectively in the equivalent control groups. Survival rates in treated patients with delayed metastases in one, two, three or more lymph nodes was 70%, 70% and 65% compared with 47%, 42% and 35% in the equivalent control groups. Treatment and control groups appeared well matched for a number of known prognostic features, including number and size of involved nodes, sex and thickness of primary tumor. Multivariate analysis indicated the effect of treatment was independent of these factors. Despite the empiricism of this approach the present results suggest that this form of therapy warrants further evaluation in a randomized controlled trial.

Keywords: Lymph Node, Melanoma, Treated Patient, Historical Control, Melanoma Cell Line

References

  • 1.Aranha GV, McKhann CF, Grace TB, Gunnarsson A, Simmons RL. Adjuvant immunotherapy of malignant melanoma. Cancer. 1979;43:1297. doi: 10.1002/1097-0142(197904)43:4<1297::aid-cncr2820430417>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  • 2.Austin FC, Boon CW. Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res. 1979;30:301. doi: 10.1016/s0065-230x(08)60900-8. [DOI] [PubMed] [Google Scholar]
  • 3.Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II) Ann Surg. 1981;193:377. doi: 10.1097/00000658-198103000-00023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Balch CM, Soong SJ, Shaw HM, Milton GW. Cutaneous melanoma. Philadelphia: J. B. Lippincott Co; 1985. An analysis of prognostic factors in 4000 patients with cutaneous melanoma; p. 338. [Google Scholar]
  • 5.Balch CM, Urist MM, Maddox WA, Milton GW, McCarthy WH. Management of regional metastatic melanoma. In: Balch CM, Milton GW, editors. Cutaneous melanoma, clinical management and treatment resuluts worldwide. Philadelpha: J B. Lippincott Co; 1985. p. 93. [Google Scholar]
  • 6.Bukowski RM, Deodhar S, Newlett JS, Greenstreet R. Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer. 1983;51:269. doi: 10.1002/1097-0142(19830115)51:2<269::aid-cncr2820510217>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 7.Burdick KH, Hawk WA. Vitiligo in a case of vaccinia virus-treated melanoma. Cancer. 1964;17:708. doi: 10.1002/1097-0142(196406)17:6<708::aid-cncr2820170604>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  • 8.Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC. Identification of a human neuroectodermal tumor antigen (OFA-1-2) as ganglioside GD2. Proc Natl Acad Sci USA. 1982;79:7629. doi: 10.1073/pnas.79.24.7629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Camacho ES, Pinksky CM, Braun DW, Golbey RB, Fortner JG, Wanebo HJ, Oettgen HF. DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer. 1981;47:2446. doi: 10.1002/1097-0142(19810515)47:10<2446::aid-cncr2820471023>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 10.Cascinelli N, Vaglini M, Nava M, Santinami M, Marolda R, Rovini D, Clemente C, Bufalino R, Morabito A. Prognosis of skin melanoma with regional node metastases. J Surg Oncol. 1984;25:240. doi: 10.1002/jso.2930250404. [DOI] [PubMed] [Google Scholar]
  • 11.Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer. 1983;52:856. doi: 10.1002/1097-0142(19830901)52:5<856::aid-cncr2820520519>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  • 12.Cox DR. Regression model and life tables. J Royal Stat Soc. 1972;B34:187. [Google Scholar]
  • 13.Dales S, Oldstone MBA. Localization at high resolution of antibody-induced mobilization of vaccinia virus hemagglutinin and the major histocompatibility antigens on the plasma membrane of infected cells. J Exp Med. 1982;156:1435. doi: 10.1084/jem.156.5.1435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Eilber FR, Townsend CM, Morton DL. Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am J Surg. 1976;132:476. doi: 10.1016/0002-9610(76)90323-8. [DOI] [PubMed] [Google Scholar]
  • 15.Everall JD, Wand J, O'Doherty CJ, Dowd PM. Treatment of primary melanoma by intralesional vaccinia before excision. Lancet. 1975;II:583. doi: 10.1016/S0140-6736(75)90172-5. [DOI] [PubMed] [Google Scholar]
  • 16.Freedman RS, Bowen JM, Herson J, Wharton JT, Rutledge FN, Hamberger AD. Virus modified homologous tumor-cell extract in the treatment of vulvar carcinoma. Cancer Immunol Immunother. 1980;8:33. [Google Scholar]
  • 17.Freedman RS, Rutledge FN, Wharton JT. Adjunctive immunotherapy with virus modified tumor cell extract in patients with high risk squamous carcinoma of the uterine cervix. Am J Clin Oncol Cancer Clin Trials. 1983;6:155. [Google Scholar]
  • 18.Gehan EA, Frereich EJ. Non randomized controls in cancer clinical trials. N Engl J Med. 1974;290:198. doi: 10.1056/NEJM197401242900405. [DOI] [PubMed] [Google Scholar]
  • 19.Gutterman JU, Richman SP, McBride CM, Burgess MA, Bartold SL, Kennedy A, Gehan EA, Mavlight G, Hersh EM. Immunotherapy for recurrent malignant melanoma. Efficacy of BCG in prolonging the postoperative disease free interval and survival. Recent Results Cancer Res. 1979;68:359. doi: 10.1007/978-3-642-81332-0_53. [DOI] [PubMed] [Google Scholar]
  • 20.Hersey P. Review of melanoma antigens recognized by monoclonal antibodies. Their functional significance and applications in diagnosis and treatment of melanoma. Pathology. 1985;17:346. doi: 10.3109/00313028509063778. [DOI] [PubMed] [Google Scholar]
  • 21.Hersey P, Balch CM. Current status and future prospects for adjuvant therapy of melanoma. Aust NZ J Surg. 1984;54:303. doi: 10.1111/j.1445-2197.1984.tb05324.x. [DOI] [PubMed] [Google Scholar]
  • 22.Hersey P, Edwards A, Murray E, McCarthy WH, Milton GW. Prognostic significance of leukocyte dependent antibody activity in melanoma patients. J Natl Cancer Inst. 1983;71:45. [PubMed] [Google Scholar]
  • 23.Hersey P, Edwards A, D'Alessandro G, MacDonald M. Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leukocyte dependent antibody activity. Cancer Immunol Immunother. 1986;22:221. doi: 10.1007/BF00200037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hilal EY, Pinksky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Braun DW, Fortner JG, Oettgen HF. Surgical adjuvant therapy of malignant melanoma with Corynebacterium parvum . Cancer. 1981;48:245. doi: 10.1002/1097-0142(19810715)48:2<245::aid-cncr2820480206>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  • 25.Hill GJ, Moss S, Fletcher W, Golomb F, Grace T. DTIC melanoma adjuvant study. Final report. Proc Am Assoc Cancer Res. 1978;19:309. [Google Scholar]
  • 26.Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 1981;66:249. [PubMed] [Google Scholar]
  • 27.Lotzova E, Savary CA, Freedman RS, Bowen JM. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol Immunother. 1984;17:124. doi: 10.1007/BF00200048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Milton GW. Some methods used in the management of metastatic melanoma. Aust J Dermatol. 1963;7:15. doi: 10.1111/j.1440-0960.1963.tb01668.x. [DOI] [PubMed] [Google Scholar]
  • 29.Mallon V, Domber EA, Holowczak JA. Vaccinia virus proteins on the plasma membranes of infected cells. II. Expression of viral antigens and killing of infected cells by vaccinia virus-specific cytotoxic T cells. Virology. 1985;145:1–23. doi: 10.1016/0042-6822(85)90197-7. [DOI] [PubMed] [Google Scholar]
  • 30.Muir PD, Gunz FW. A cytogenetic study of eight human melanoma cell lines. Pathology. 1979;11:597–606. doi: 10.3109/00313027909059039. [DOI] [PubMed] [Google Scholar]
  • 31.Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Pope JH, Morrison L, Moss DJ, Parsons PG, Regius Mary., Sr. Human malignant melanoma cell lines. Pathology. 1979;11:191. doi: 10.3109/00313027909061945. [DOI] [PubMed] [Google Scholar]
  • 33.Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. J Exp Med. 1982;155:1133. doi: 10.1084/jem.155.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Roenigk HH, Deodhar S, St. Jacques R, Burdick K. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol. 1974;109:668. [PubMed] [Google Scholar]
  • 35.Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with stage II cutaneous malignant melanoma. Ann Surg. 1985;201:103. [PMC free article] [PubMed] [Google Scholar]
  • 36.Sacks H, Chalmers TC, Smith H. Randomized versus historical controls for clinical trials. Am J Med. 1982;72:233. doi: 10.1016/0002-9343(82)90815-4. [DOI] [PubMed] [Google Scholar]
  • 37.Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T. The augmentation of tumor specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus reactive helper T cells. Eur J Immunol. 1984;14:839–843. doi: 10.1002/eji.1830140913. [DOI] [PubMed] [Google Scholar]
  • 38.Sinkovics JG, Papadopoulos NE, Plager G. Advances in comparative leukemia research on leukemia and related diseases. North Holland Inc, NY: Elsevier; 1981. Viral oncolysate in immunotherapy of human tumors; p. 613. [Google Scholar]
  • 39.Veronesi U, Adamua J, Aubert C, et al. WHO study group trial No. 6. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307:913. doi: 10.1056/NEJM198210073071503. [DOI] [PubMed] [Google Scholar]
  • 40.Wallack MK. Specific immunotherapy with vaccinia oncolysates. Cancer Immunol Immunother. 1981;12:1. doi: 10.1007/BF01740939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wallack MK, Michaelides M. Serologic responses to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma cell lysates. Surgery. 1984;96:791. [PubMed] [Google Scholar]
  • 42.Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B, Johnson J. A new approach in specific, active immunotherapy. Cancer. 1977;39:560. doi: 10.1002/1097-0142(197702)39:2<560::aid-cncr2820390227>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  • 43.Watanabe T, Pukel CS, Takeyama H, Lloyd KO, Shiku H, Li LTC, Travassos LR, Oettgen HF, Old LJ. Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med. 1982;156:1884. doi: 10.1084/jem.156.6.1884. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES